So regarding the frontline management of chronic graft-versus-host disease, this is what’s important. First is to perform the diagnosis of chronic graft-versus-host disease. This is because the diagnosis of chronic graft-versus-host disease is based on the presence of distinctive things, or based on the distinctive things plus a biopsy according to the NIH recommendations. Until the diagnosis is performed you can perform the scoring, so based on the organs and then the overall chronic graft-versus-host disease grading according to the NIH, which I have already discussed...
So regarding the frontline management of chronic graft-versus-host disease, this is what’s important. First is to perform the diagnosis of chronic graft-versus-host disease. This is because the diagnosis of chronic graft-versus-host disease is based on the presence of distinctive things, or based on the distinctive things plus a biopsy according to the NIH recommendations. Until the diagnosis is performed you can perform the scoring, so based on the organs and then the overall chronic graft-versus-host disease grading according to the NIH, which I have already discussed. To perform this scoring is very important, not only for the patient follow up, but also to know if you need some treatment. Because we need first-line treatments based on steroids, one milligram per kilo per day for moderate or severe chronic graft-versus-host disease [inaudible] we only need to start the system [inaudible] in case of involvement of the joint or fascia. So, just to conclude, the first-line treatment remains based on steroids. There are no benefits from adding any additional treatments so far. Maybe in the future and based on future clinical trials we’ll have some benefit to add some additional treatments, but this is not the case until now.
